Re: Michael B. Atkins, Elizabeth R. Plimack, Igor Puzanov, et al. Axitinib in Combination with Pembrolizumab in Patients with Advanced Renal Cell Cancer: A Non-randomised, Open-label, Dose-finding, and Dose-expansion Phase 1b Trial. Lancet Oncol 2018;19:405-15

Eur Urol. 2018 Aug;74(2):e50. doi: 10.1016/j.eururo.2018.04.015. Epub 2018 Apr 27.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • Axitinib*
  • Carcinoma, Renal Cell*
  • Humans
  • Kidney Neoplasms

Substances

  • Antibodies, Monoclonal, Humanized
  • Axitinib
  • pembrolizumab